Ignite Creation Date:
2024-05-06 @ 12:42 AM
Last Modification Date:
2024-10-26 @ 10:53 AM
Study NCT ID:
NCT01634763
Status:
COMPLETED
Last Update Posted:
2020-12-19
First Post:
2012-07-03
Brief Title:
Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase ALK
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase ALK |
Keywords:
| Name | View |
|---|---|
| Phase I open-label dose escalation oral LDK378 Japanese patients with tumors characterized by ALK genetic alterations | View |